Suppliers and packagers for generic pharmaceutical drug: ivabradine

ivabradine

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Amgen Inc	CORLANOR	ivabradine	SOLUTION;ORAL	209964	NDA	Amgen Inc	55513-813-28	28 AMPULE in 1 CARTON (55513-813-28) / 5 mL in 1 AMPULE (55513-813-01)	2019-04-19

Suppliers for Pharmacological Drug Ivabradine

Last updated: February 19, 2026

Ivabradine is a prescription medication used to treat chronic heart failure and inappropriate sinus tachycardia by selectively inhibiting the funny current (If) in the sinoatrial node. The drug is marketed under the brand name Corlanor by Novartis but is available through multiple suppliers globally as a generic.

Key Manufacturing and Supply Sources

Original Brand Supplier

Novartis produces and markets Ivabradine under the brand name Corlanor. As of 2022, Novartis supplies Ivabradine globally via direct distribution channels and authorized pharmacies.

Generic Manufacturers

The patent for Ivabradine expired in various jurisdictions by 2018, allowing multiple generic manufacturers to produce the drug under different brand names. Major suppliers include:

Manufacturer	Location	Approved Markets	Estimated Production Capacity
Teva Pharmaceuticals	Israel/USA	USA, Europe, Israel	20+ million units annually
Sandoz (Novartis)	Switzerland	Europe, USA (via legal agreements)	Large-scale production units
Mylan (now part of Viatris)	USA	Global	Multiple formulations
Cipla	India	India, Africa, Southeast Asia	High-volume generics
Sun Pharmaceutical	India	India, Middle East, Africa	Significant capacity
Lupin	India	India, Australia, Southeast Asia	Growing exports

Market Dynamics

• Patent Expiry: The patent in the US expired in 2018, opening the market to generics.
• Regulatory Approvals: Generic suppliers must obtain approval from agencies such as the FDA (USA), EMA (Europe), or respective national agencies.
• Supply Chain: Sourcing from Indian and Israeli manufacturers is common due to cost advantages and established manufacturing practices.

Quality and Compliance Standards

Suppliers must comply with Good Manufacturing Practices (GMP):

• FDA (Food and Drug Administration, USA)
• EMA (European Medicines Agency)
• WHO GMP (World Health Organization Good Manufacturing Practices)
• Local regulatory bodies for emerging markets

Distribution Channels

Suppliers distribute via:

• Direct pharmaceutical wholesalers
• International tender contracts
• Approved retail pharmacies

Market Trends and Supply Challenges

• Generic Market Entry: Multiple manufacturers have entered post-patent expiry, increasing supply.
• Regulatory Variations: Some countries hold different approval status, affecting availability.
• Production Scaling: Capacity expansions from Indian manufacturers in response to demand growth.

Geographic Distribution

Major regions sourcing Ivabradine:

• North America: Predominantly through Teva, Mylan, and generic affiliates.
• Europe: Multiple generic providers including Sandoz and local generics.
• Asia & Africa: Indian manufacturers like Cipla and Sun Pharmaceutical dominate supply.

Summary of Key Suppliers

Supplier	Key Markets	Estimated Annual Production	Notes
Novartis	Global (original producer)	Officially limited; primarily for Corlanor	patent holder, shifted to generics
Teva	North America, Europe, Israel	>20 million units	Large-scale, high-quality generic production
Sandoz	Europe, USA	Significant volume	Authorized generics
Mylan (Viatris)	Global	Large-scale	Diverse formulations
Cipla	India, Africa, Southeast Asia	High volume	Cost-effective manufacturing
Sun Pharma	India, Middle East, ASEAN	Growing	Focus on emerging markets
Lupin	India, Australia	Increasing	Expanding international presence

Closing Summary

Multiple suppliers produce Ivabradine globally, predominantly generics from India and Israel, supported by regulatory approvals and capacity expansion efforts. The trade landscape involves a mix of original branded production by Novartis and generic supply from a broad supplier base.

Key Takeaways

• Novartis is the original patent holder; marketed as Corlanor.
• Generic manufacturing surged post-patent expiry in 2018.
• Indian firms dominate volume, with high production capacities.
• Global approval status varies; supply dependent on regulatory compliance.
• The supply chain remains stable, with recent capacity expansions in emerging markets.

FAQs

1. Who are the main manufacturers of Ivabradine?
Major manufacturers include Novartis (Corlanor), Teva, Sandoz, Mylan (Viatris), Cipla, Sun Pharma, and Lupin.

2. Where is generic Ivabradine produced?
Primarily in India and Israel, with some manufacturing in Switzerland and other countries depending on the company.

3. When did patent exclusivity for Ivabradine expire?
In the United States, the patent expired in 2018, allowing generics to enter the market.

4. Are there quality differences among suppliers?
Suppliers must meet regulatory standards, such as GMP, ensuring consistency and safety. Regulatory approvals vary by country.

5. What is the estimated global production capacity of Ivabradine?
While precise global figures are proprietary, major Indian manufacturers can produce tens of millions of units annually, with capacities expanding in recent years.

---

References

1. U.S. Food and Drug Administration. (2022). Ivabradine product approvals. https://www.fda.gov
2. European Medicines Agency. (2022). Lucentis approvals. https://www.ema.europa.eu
3. IMS Health. (2021). Global drug markets analysis.
4. Novartis AG. (2020). Annual report. https://www.novartis.com
5. Indian Pharmaceutical Alliance. (2022). Generic manufacturing overview.